Indegene Ltd Q4 FY2024 Concall Summary

Key Takeaways

• Steady FY24, non-linear path ahead: Revenue grew 12.3% for the full year despite a cyclical dip in top-30 pharma spending, while EBITDA margins expanded 286 bps to 22.6%. Management expects growth to continue but warns it will not be linear.
• Core enterprise business is the anchor: The ECS and EMS segments, 82% of revenue, grew 11% organically, driven by outsourcing, digital shift, and centralization. These deep-standing engagements provide a broad, index-like revenue base not tied to any single product or therapy.
• Margin recovery is systemic, not temporary: The 286 bps EBITDA margin expansion to 22.6% came from automation and process improvements that management calls systemic. The long-run target range is 22%-24%, with reinvestment during high-growth periods.
• Client base is diversifying fast: Top-20 pharma concentration fell from 78% to 69% over three years, while active customers grew from 44 to 63. The top-five client share also declined as newer customers grew faster.
• What to watch next quarter: Whether the emerging biotech headwind persists, the pace of operating leverage in the still-dilutive Omnichannel Activation segment, and deployment of IPO proceeds now that the company is debt-free.

Revenue Engine & Client Dynamics

• Core segments delivered: ECS and EMS grew 11% organically, fueled by pharma's structural shift to digital and centralized operations. Omnichannel Activation grew 13% including the CultHealth inorganic contribution, while the Others segment grew 30% organically.
• Revenue base is sticky and broad: Revenues are not linked to any single product or therapeutic area, functioning more like an index of the pharma industry. The 82% enterprise commercial and medical business consists of deep-standing engagements that take months to set up, not one-off projects.
• Client concentration is structurally declining: Top-20 pharma share dropped from 78% in FY21 to 69%, reflecting growth within those accounts plus new customer additions. Active customers rose from 44 to 63. The top-five client share also declined because newer customers are growing faster from a smaller base.
• Geographic mix mirrors industry spend: 97% of revenue comes from the Americas and Europe, consistent with where global life science spending concentrates, with a slight overweight to Europe relative to the industry.
• Emerging biotech remains a drag: This segment de-grew during the year, specifically hurting Omnichannel Activation. The CultHealth acquisition offset the decline, but management stays cautious while continuing to invest with a longer-term view.
• Pharma's cyclical dip explains the slowdown: Top-30 pharma companies declined revenues by 7.1% in 2023, a cyclical event that occurs every 10-15 years. 2024 was also a consolidation year after heavy activity. Indegene still grew through both headwinds.

Manish Gupta: "The growth will not be linear. So there will be years and quarters of high growth. There will be some quarters and years of lower growth. But nevertheless, we will continue to grow."

Margins: Recovery & Reinvestment Logic

• FY24 margin expansion was systemic: EBITDA margin rose 286 bps to 22.6%, driven by operational efficiencies, automation, and people and process improvements. Management believes these changes are structural and will persist.
• Segment margins tell a two-speed story: ECS and EMS margins are stable and growing from productivity measures. Omnichannel Activation and Others, roughly 18% of revenue, are not yet margin-accretive at the segment level. Operating leverage is expected to close that gap as they scale.
• The growth-versus-margin trade-off is explicit: If regular growth runs 10%-15%, margins might dip roughly one percentage point to enable it. When growth hit roughly 70% through 2022, margins fell by three percentage points. Management says it knows which levers to pull to bring margins back.
• Long-run EBITDA target is 22%-24%: The company will strive to operate in that range, but will reinvest during periods of high growth as the market responds. Historically, Indegene operated above 22% before the post-COVID investment cycle pushed margins below 20%.
• Zero-debt status adds a tailwind: With IPO proceeds repaying all debt, interest costs should fall to zero, favorably impacting earnings going forward.

Manish Gupta: "If my growth from a regular thing is going to be 10%-15% up, then we might drop, to enable that growth, drop the margins by, let's say, a percentage or so. This is exactly what happened until, let's say, 2022. That we grew at 70% or so. Hence, our margins came down by 3 percentage points."

Business Model: Not IT Services

• Indegene works the business side, not the CIO side: The company partners with P&L owners, brand heads, therapeutic heads, global commercial ops, and chief medical officers. IT services firms focus on sales force and cloud implementation for the CIO. Indegene's work is non-discretionary: FDA filings, customer outreach, medical communications.
• Talent mix is fundamentally different: The workforce combines medical doctors, PhDs, pharmacologists, software engineers, and creative professionals. Managing this complexity across multiple geographies is a core capability that distinguishes Indegene from traditional IT services.
• Why pharma buys from Indegene: The industry is open to partnerships given its complexity. The digital shift created complexity in sales and marketing across iPads, email, WeChat, EMR integration, and doctor websites spanning 40-50 countries. Indegene combines medical expertise with technology skills and platforms built over a long period.
• Asset-light with low capex: Capex typically runs roughly 1% of revenues, and management expects that to continue in the near future.

Manish Gupta: "As Indegene, we are working primarily on the business side, with the P&L owners, brand heads, therapeutic heads, global commercial ops, chief medical officers... Opportunistically, probably we'll be on the CIO side. It's completely reversed. So, to that extent, what we do is non-discretionary in nature."

M&A & Capital Allocation

• Trilogy acquisition closed in late March: The 100% acquisition of a Germany-based medical writing business in regulatory affairs closed around March 22. It is non-material, with no revenue or margin contribution in Q4; FY24 performance is entirely organic.
• CultHealth integrated into Omnichannel Activation: Acquired in October 2022, it contributed to the segment's 13% reported growth.
• Tuck-in M&A remains the strategy: Cash on the balance sheet will fund strategic tuck-in acquisitions, following a track record of identifying targets, buying at the right price, integrating them, and expanding the client and solution footprint.
• Capital return is on the table: Management feels confident it can deploy funds prudently. If not, the Board is willing to return cash to shareholders in the most efficient way.

Manish Gupta: "We feel confident to be able to deploy our funds prudently. That said, even if not, our Board will be more than willing to return our cash to shareholders in the most efficient way."

People & Capacity

• Campus hiring is scaling up: Offers made are higher than last year, and those hires will be joining. Management declined to give a specific employee count target for FY25 or FY26.
• Post-COVID growth required temporary capacity measures: During the high-growth period when the digital shift accelerated, Indegene used subcontracting and built capacity ahead of demand. Those temporary measures are now unwinding as margins recover.

Guidance & Commitments

Key Metrics